Rein Therapeutics is advancing LTI-03 into the enrolling RENEW Phase 2 trial, identified as NCT06968845, for idiopathic pulmonary fibrosis. The move matters to investors because the company is targeting a potentially fatal disease while warning that Phase 2 data may not arrive in the second half of 2026 and cash may fund operations only into the first quarter of 2028.
Key Highlights
- LTI-03’s Phase 1b clinical trial met its primary endpoint, with the candidate described as well-tolerated.
- The treatment is delivered directly to the lungs through a dry powder inhaler and is designed to affect multiple fibrosis pathways.
- Rein Therapeutics said its present cash and cash equivalents may not fund operations into the first quarter of 2028.
Rein Therapeutics, Inc. (NASDAQ: RNTX) is advancing LTI-03 into a Phase 2 trial for idiopathic pulmonary fibrosis, with the RENEW study now enrolling. The candidate is positioned as a potential treatment for a fatal disease marked by progressive lung scarring.
LTI-03 Moves Into Enrolling RENEW Study
A September 4, 2026 presentation describes LTI-03 as a direct-to-lung therapy delivered through a dry powder inhaler. Rein says the candidate combines inhibition of profibrotic signaling with support for alveolar epithelial cells. Its Phase 1b trial met the primary endpoint, and the presentation says LTI-03 was well-tolerated with no treatment-related serious adverse events. Biomarker results were directionally consistent with preclinical findings, while the RENEW Phase 2 study carries the identifier NCT06968845.
IPF Opportunity and Development Risks
The presentation describes idiopathic pulmonary fibrosis as a fatal, age-related disease and estimates U.S. prevalence at 14 to 43 per 100,000, with approximately 40,000 to 110,000 adults affected. The filing says three drugs were approved for IPF as of September 2026 and that Ofev generated more than $4B in sales. The materials warn that Phase 2 data may not be reported in the second half of 2026 and that current cash and cash equivalents may not fund operations into the first quarter of 2028.



Please wait processing your request...